Lupin News

Several stocks, including JSW Steel, Tata Motors, Mazagon Dock, RVNL, Lupin, Molbio, Purple Style Labs, HEG, Lemon Tree, Shiprocket, Nava, and Behari Lal, are e

Pharmaceutical company Lupin has received USFDA approval for its Modafinil tablets, intended to treat excessive sleepiness in adults. The drug is bioequivalent

Lupin believes the GLP-1 market may be smaller than anticipated and is planning its next generation of weight-loss drugs, including fortnightly bofenglutide and

Lupin's subsidiary, VISUfarma BV, has secured exclusive rights to commercialize the YUVEZZI eye drop in key European markets. This ophthalmic product is designe

Lupin received USFDA approval for generic Pitolisant Tablets, enhancing its US portfolio and specialty generics presence. Despite this positive regulatory news,

Lupin reported strong Q1 FY27 results with sales rising 33.3% to ₹8,217 crore, EBITDA increasing 42.8% to ₹2,580 crore, and profit after tax growing 16% to ₹1,4

Lupin Ltd reported a 16% rise in Q1 profit after tax, driven by a 42% increase in US market sales and a nearly 14% rise in Indian sales.

Several prominent companies, including Life Insurance Corporation of India (LIC), Trent, Hero Motocorp, Lupin, Emcure Pharmaceuticals, Britannia Industries, and

Lupin Limited has launched its Sugammadex Injection in the United States after receiving approval from the US Food and Drug Administration. The company claims i

The Indian stock market experienced a significant sell-off on July 22, with the Nifty 50 closing 0.77% lower due to Middle East tensions and concerns over US ta

Pharma stocks including Lupin, Aurobindo, and Cipla fell by up to 2.9% due to pressure from Donald Trump's tariff roadmap, which rattled market sentiment.

Shares of Sun Pharma, Aurobindo, Lupin, and Zydus Life are in focus following Trump's announcement of a two-year zero tariff policy on generics. US exports cons

Lupin has acquired an 82.2% stake in Kaveri Therapeutics and licensed two oncology assets for $1.6 million, with Kaveri set to advance the oncology program thro